Efficiency of Mitoxantrone in Patients with Progressive Forms of Multiple Sclerosis

V.V. Vasylovskyi, N.P. Voloshyna, T.V. Nehreba, M.Ye. Chernenko


We have examined the efficacy, safety and tolerability of mitoxantrone in 67 patients with progressive forms of multiple sclerosis (MS).
There was carried out the analysis of clinical and radiological fin-dings in 19 patients with primary progressive (PP) and in 48 patients with secondary progressive (SP) MS treated with second-line cytostatic — mitoxantrone. Evaluation of clinical and radiological activity of the disease, based on the treatment outcomes, was performed immediately after the course of mitoxantrone administration and annually for 2 years after its completion. The following parameters were taking into account: the dynamics of the severity of neurological deficit according to the data of EDSS, the presence and duration of stabilization phase, the rates and variants of further progression, the nature of prognosis, the number of gadolinium-enhanced lesions according to the MRI findings. Considering these indicators, there have been developed the criteria of high, moderate and low effectiveness of treatment.
By the end of mitoxantrone administration, the high efficiency of treatment, in the form of partial regression of neurological deficit on the background of stabilization phase, was obtained in 25 % of patients with SPMS and in 21.1 % — with PPMS, in uncertain nature of prognosis; the moderate efficiency as sustained stabilization also prevailed in patients with uncertain prognosis — in 50.0 % with SP and in 36.8 % with PP; low efficiency, in the form of decrease in steady progression and its transformation into more favorable progressive variant, was determined in 22.9 % of patients with SP and in 26.3 % of patients with PP in unfavorable prognosis.
By the end of the two-year follow-up, a positive therapeutic effect of mitoxantrone with high to moderate efficacy was maintained in 50.0 % of patients with SP and in 42.1 % — with moderate efficacy in PP. During this period, the negative dynamics with the selective reorganization of success rates was obtained in 20 (41.6 %) patients with for SP and in 11 (57.9 %) — with PPMS.
Mitoxantrone, according to the MRI monitoring, slows the radiological activity of inflammatory process, reduces the number of new confirmed gadolinium-enhanced lesions, but has no effect on the overall neurodegenerative process that depends on the duration, severity and type of MS with prevalence in PP.
Conclusion. There has been proved the clinical and radiological efficacy of cytostatic mitoxantrone as a method of de-escalation immunosuppressive therapy in severe, almost incurable progressive forms of MS, considering the course, nature of prognosis, severity of neurological deficit, rates and variants of progression.


multiple sclerosis; mitoxantrone; efficacy of treatment; clinical and radiological activity of disease


Волошина Н.П. Рассеянный склероз в Украине: распространенность, течение, прогноз, лечение, фармакоэкономика [Текст] / Н.П. Волошина, В.И. Тайцлин, Т.В. Негреба, А.Г. Лещенко, Л.Ф. Шестопалова, Е.Е. Гант, Г.Д. Перцев, Т.И. Негрич, И.Л. Левченко, С.В. Федосеев, В.В. Василовский, Л.И. Дьяченко, Т.Н. Ткачева, М.Е. Черненко, В.А. Кожевникова // Український вісник психоневрології. — 2007. — Т. 15, вып. 1 (50). — С. 6-21.

Волошин П.В. Современные аспекты рассеянного склероза: патогенез, особенности течения в Украине, диагностика, стандарты патогенетической терапии [Tекст] / П.В. Волошин, Н.П. Волошина, В.И. Тайцлин, А.Г. Лещенко, Т.В. Негреба, Т.И. Негрич, Т.В. Негреба, И.Л. Левченко, В.В. Василовский, Г.Д. Перцев, Л.И. Дьяченко, О.В. Егоркина, С.В. Федосеев, В.А. Коршняк, Т.Н. Ткачева, М.Е. Черненко // Нейрон ревю. Журнал клинических нейронаук. — 2007. — № 3. — С. 4-26.

Волошина Н.П., Негреба Т.В., Левченко І.Л., Ткачова Т.М., Єгоркіна О.В. Прогностичні критерії при різних типах перебігу розсіяного склерозу. Свідоцтво про реєстрацію авторського права на науковий твір № 39160 від 14.07.2011 р.

Негреба Т.В. Течение и прогноз современных форм рассеянного склероза. Свідоцтво про реєстрацію авторського права на науковий твір № 30251 від 15.09.2009.

Евтушенко С.К., Гончарова Я.А., Симонян В.А., Филимонов Д.А., Грищенко А.Б. Современные аспекты аддитивной терапии рассеянного склероза // Український вісник психоневрології. — 2010. — Т. 18, № 3 (64). — С. 79-80.

Differential diagnosis of MS and other demyelinating di-seases // 11th Congress of the EFNS. Feaching Conrse 13. — Brussels, 2007.

Lucchinetti C. Yelero of geinity multiple sclerosis lesions: implication for the patogenesis of demielination [Text] / C. Lucchinetti, W. Bruck, J. Parini et al. // Ann. Neurol. — 2000. — Vol. 47. — P. 707-717.

Beutler E. Cladribine (2-chlorodeoxyadenosine) [Text] / E. Beutler // Lancet. — 1992. — Vol. 340. — P. 952-956.

Fidler J.M. Selective immunomodulation by the intineoplastic agent mitoxantrone [Text] / J.M. Fidler, S.Q. Deloy, F.R. Smith et al. // J. Immunol. — 1996. — Vol. 136. — P. 2747-2754.

Lenk H. Mitoxantrone mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomans, and toxicity [Text] / H. Lenk, U. Muller, S. Tanneberger // Anticancer Res. — 1999. — 7. — P. 1257-1264.

Weilbach F.X. Mitoxantrone-in-duced immunological changes in MS hatients — ex vivo studies on proliferation and cell death of peripheral blood leukocytes [Text] / F.X. Weilbach, A. Chan, K.V. Toyka et al. // J. Neurol. — 2002. — Vol. 249. — P. 113.

Шмидт Т.Е. Рассеянный склероз [Текст] / Т.Е. Шмидт, Н.Н. Яхно. — М.: МЕДпресс-информ, 2010.

Hohlfeld R. The neuroprotective effect of inflammation: implication for the therapy of multiple sclerosis [Text] / R. Hohlfeld, M. Kerschensteiner, C. Stadelmann et al. // J. Neuroimmunol. — 2000. — Vol. 107. — P. 161-166.

Crossley R.J. Clinical safety and tolerance of mitoxantrone [Text] / R.J. Crossley // Semin. Oncol. — 1994. — Vol. 11. — P. 54-58.

Hartung H.P. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind. randomised, multicentral trial. [Text] / H.P. Hartung, R. Goncette, N. Konig // Lancet. — 2002. — Vol. 360. — P. 2018-2025.

Mauch E. Mitoxantrone in the treatment of patients with multiple sclerosis: a large single centre experience [Text] / E. Mauch, S. Eisenmann, A. Hahn et al. // Mult. Scler. — 1999. — Vol. 5. — P. 366.

Edan G. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4-year mean follow-up study [Text] / G. Edan, D. Brochet, M. Clanet et al. // Neorology. — 2004. — Vol. 62. — P. 493.

Polman C.H. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria [Text] / C.H. Polman, S.C. Reingold, Benwell Betal // Annals of Neurology. — 2011. — 69 (2). — 292-302.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта